Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dynavax Technologies Corp.

This article was originally published in Start Up

Executive Summary

Dynavax Technologies Corp. is developing vaccines to permanently alter immune system and inflammatory system responses. Its technology is based on proprietary artificial immunostimulatory DNA sequences, termed ISS, which act as a signal system and change the Th1/Th2 balance. In cases of allergies or asthma, the company's initial therapeutic focus, ISS administered with specific antigens drives the immune response from Th2 to Th1 to prevent initiation of the inflammatory process.


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts